Azole derivatives as apelin receptor agonist

Patent metadata

Field	Value
Publication number	US-11155525-B2
Application number	US-202016853604-A
Country	US
Kind code	B2
Filing date	Apr 20, 2020
Priority date	Nov 24, 2015
Publication date	Oct 26, 2021
Grant date	Oct 26, 2021

Abstract

The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —N═ or —CH═, X2 represents —CH═ or —N═, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.

First claim

What is claimed is:

1. A compound represented by formula (I), or a pharmacologically acceptable salt thereof:

wherein
X 1 represents —CH═,
X 2 represents —CH═,
R 1 and R 2 each independently represent a C 1 to C 6 alkyl group, a C 1 to C 6 alkoxy group, or a halogeno group (the C 1 to C 6 alkyl group and the C 1 to C 6 alkoxy group are each optionally substituted by 1 to 3 fluoro groups),
R 3 is a furyl group, a thienyl group, a pyridyl group, a phenyl group, a n-butyl group, or a cyclopentyl group (the furyl group, the thienyl group, the pyridyl group, and the phenyl group are each optionally substituted by 1 or 2 identical or different groups selected from a methyl group and a halogeno group); and

2. The compound according to claim 1 , or a pharmacologically acceptable salt thereof, wherein R 1 and R 2 are each independently a C 1 to C 6 alkoxy group or a C 1 to C 6 alkyl group.

3. The compound according to claim 1 , or a pharmacologically acceptable salt thereof, wherein R 3 is a furyl group or a thienyl group (the furyl group or the thienyl group are each optionally substituted by 1 or 2 identical or different groups selected from a methyl group and a halogeno group).

4. The compound according to claim 1 , or a pharmacologically acceptable salt thereof, wherein R 3 is a 5-methylfuran-2-yl group.

5. The compound according to claim 1 , or a pharmacologically acceptable salt thereof, wherein R 4 is

6. The compound according to claim 1 , or a pharmacologically acceptable salt thereof, wherein R 4 is

7. The compound according to claim 1 , or a pharmacologically acceptable salt thereof, wherein R 4 is

8. The compound according to claim 1 , or a pharmacologically acceptable salt thereof, wherein R 4 is

9. The compound according to claim 1 , or a pharmacologically acceptable salt thereof, wherein R 4 is

10. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmacologically acceptable salt thereof, as an active ingredient.

11. A method for treating a disease, comprising administering a pharmacologically effective amount of a compound according to claim 1 , or a pharmacologically acceptable salt thereof.

12. The method according to claim 11 , wherein the disease comprises cardiovascular disease, coronary heart disease, stroke, heart failure, systolic heart failure, diastolic heart failure, diabetic heart failure, heart failure with preserved ejection fraction, cardiomyopathy, myocardial infarction, left ventricular dysfunction, left ventricular dysfunction after myocardial infarction, cardiac hypertrophy, myocardial remodeling, myocardial remodeling after infarction, myocardial remodeling after cardiac surgery, valvular heart disease, metabolic disease, metabolic syndrome, insulin resistance, diabetes mellitus, diabetic late complications, diabetic macrovasculopathy, diabetic microvasculopathy, diabetic nephropathy, diabetic retinopathy, diabetic neuropathies, cardiac autonomic neuropathy, CNS-dependent disturbed fluid homeostasis, CNS-independent disturbed fluid homeostasis, acute renal failure, chronic renal failure, hypertension, pulmonary hypertension, portal hypertension, systolic hypertension, vascular disease, vascular hypertrophy, vascular remodeling, vascular stiffness, atherosclerosis, peripheral arterial occlusive disease (PAOD), restenosis, thrombosis, vascular permeability disorder, cardiac, renal, or retinal disorder caused by ischemia, or cardiac, renal, or retinal disorder caused by reperfusion.

13. The method according to claim 11 , wherein the disease comprises cardiovascular disease, coronary heart disease, stroke, heart failure, systolic heart failure, diastolic heart failure, diabetic heart failure, heart failure with preserved ejection fraction, cardiomyopathy, myocardial infarction, left ventricular dysfunction, left ventricular dysfunction after myocardial infarction, cardiac hypertrophy, myocardial remodeling, myocardial remodeling after infarction, myocardial remodeling after cardiac surgery, or valvular heart disease.

14. The method according to claim 11 , wherein the disease comprises metabolic disease, metabolic syndrome, insulin resistance, diabetes mellitus, diabetic late complications, diabetic macrovasculopathy, diabetic microvasculopathy, diabetic nephropathy, diabetic retinopathy, diabetic neuropathies, or cardiac autonomic neuropathy.

15. The method according to claim 11 , wherein the disease comprises CNS-dependent disturbed fluid homeostasis, CNS-independent disturbed fluid homeostasis, acute renal failure, chronic renal failure, hypertension, pulmonary hypertension, portal hypertension, or systolic hypertension.

16. The method according to claim 11 , wherein the disease comprises vascular disease, vascular hypertrophy, vascular remodeling, vascular stiffness, atherosclerosis, peripheral arterial occlusive disease (PAOD), restenosis, thrombosis, vascular permeability disorder, cardiac, renal, or retinal disorder caused by ischemia, or cardiac, renal, or retinal disorder caused by reperfusion.

17. The method according to claim 11 , wherein the disease comprises pulmonary hypertension.

18. A method for agonizing apelin receptor activity in a subject, comprising administering a compound according to claim 1 , or a pharmacologically acceptable salt thereof, to a subject.

19. A method for treating a disease or condition treatable by agonizing apelin receptor, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1 , or a pharmacologically acceptable salt thereof, wherein the disease or condition is cardiovascular disease, coronary heart disease, stroke, heart failure, systolic heart failure, diastolic heart failure, diabetic heart failure, heart failure with preserved ejection fraction, cardiomyopathy, myocardial infarction, left ventricular dysfunction, left ventricular dysfunction after myocardial infarction, cardiac hypertrophy, myocardial remodeling, myocardial remodeling after infarction, myocardial remodeling after cardiac surgery, valvular heart disease, metabolic disease, metabolic syndrome, insulin resistance, diabetes mellitus, diabetic late complications, diabetic macrovasculopathy, diabetic microvasculopathy, diabetic nephropathy, diabetic retinopathy, diabetic neuropathies, cardiac autonomic neuropathy, CNS-dependent disturbed fluid homeostasis, CNS-independent disturbed fluid homeostasis, acute renal failure, chronic renal failure, hypertension, pulmonary hypertension, portal hype

Assignees

• Sanford Burnham Prebys Medical Discovery Inst

Inventors

• Ikeda Takuya
• Kobayashi Yoshiyuki
• Miyoshi Naoki
• Suzuki Osamu
• Nagayama Takahiro
• Tsuji Takashi
• Smith Layton H
• Pinkerton Anthony B

Classifications

• C07D405/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D403/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title

• G16C20/50

  Molecular design, e.g. of drugs · CPC title

• C07D409/14

  containing three or more hetero rings · CPC title

• G16B25/00

  ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression · CPC title